Business Wire

Nebula Genomics Raises $4.3M Seed Financing From Leading Tech and Biotech VCs

Del

Nebula Genomics announced today that it has raised $4.3M million in seed financing with participation from 10 leading venture capital firms. The funds will support the company’s mission to usher in the era of personal genome sequencing by creating a trusted, secure, and decentralized marketplace for genomic data. The company also has forged a partnership with Veritas Genetics, the leading whole genome sequencing and interpretation company, that will connect the Nebula marketplace to Veritas’ Arvados open-source software platform.

This financing round includes many of the best-known venture firms investing in innovative entrepreneurs in genomics and blockchain. Investors include Khosla Ventures, Arch Venture Partners, Fenbushi Capital, Mayfield, F-Prime Capital Partners, Great Point Ventures, Windham Venture Partners, Hemi Ventures, Mirae Asset, Hikma Ventures and Heartbeat Labs.

“As a people-first firm and early-stage investor, we always begin with the entrepreneur as our first step,” said Tim Chang of Mayfield. “Kamal and Dennis have a unique vision of leveraging blockchain to enable consumer genetic sequencing at scale, and the involvement of genomics pioneer George Church makes this a dream team. When you combine that with Nebula’s unique business model and incentive design, we believe the company can grow into a leading pioneer of the genomics age.”

The coming genomic age holds immense promise for the development of personalized medicine, improving patient outcomes, and improving the quality of human life. To realize that potential, researchers need streamlined access to the individual genomes of millions or billions of people -- individuals who are reluctant to share their genomes today because of concerns over privacy, trust, control and cost. Nebula’s marketplace will address those concerns directly, using blockchain and other technologies to put consumers in control of their genomic data, as well as by compensating individuals directly for the use of their data. That will encourage an ever-growing number of consumers to participate in the marketplace and create an essential resource for advances in research.

“Our investors, along with Veritas, share our commitment to lowering access barriers to genomic data, and solving one of the primary roadblocks preventing personalized medicine becoming a reality today,” said Kamal Obbad, CEO & co-founder of Nebula Genomics. “With this funding we are moving closer to a new age in personalized medicine.”

“As genome sequencing inches towards mass adoption, security and privacy concerns remain core barriers,” said Robert Nelsen, managing director of Arch Venture Partners, whose past investments included Illumina and GRAIL. “Nebula’s team has architected a unique decentralized system that protects data while still making it easily accessible for researchers.”

The partnership with Veritas enables the Nebula marketplace to build upon the existing advantages of the open-source software platform Arvados. Developed by Veritas, Arvados is the most-widely used open-source platform for storing, sharing and analyzing genomic data – currently exceeding 20 petabytes of data. It is used globally by researchers, pharmaceutical companies and research institutions.

One of the unique features of the federated Arvados platform is that it allows consented data to be queried regardless the data’s location. Therefore, various data sets can be physically stored and managed according to local rules and regulations, especially those concerning privacy and protection. The Nebula marketplace will leverage this federation to enable individuals and institutions to exchange and trade access to the data with the benefits of blockchain-based privacy and smart contracts.

“Privacy and security issues are on everyone's mind and blockchain is a promising way to address both,” said Mirza Cifric, CEO of Veritas Genetics. “As our own database grows to many petabytes, together with the Nebula team we are taking the lead in our industry to protect the privacy of consumers while enabling them to participate in research and benefit from the blockchain-based marketplace Nebula is building.”

An innovative health data marketplace

Nebula’s talent and deep experience in adapting technologies for the blockchain, combined with Veritas’ genomic expertise and platform, will enable the creation of a large and trusted genomic and health data marketplace to accelerate genomic data growth and facilitate genomic data access. Data buyers will subsidize the cost of genome sequencing and interpretation, providing a strong incentive for consumers to participate.

Once their genome is sequenced, consumers will store and manage their own data via Arvados, an open source distributed biomedical data storage and computing platform widely used by researchers in industry and at academic institutions. Consumers will be able to choose how much and with whom their data is shared, with all the security and transparency advantages offered by blockchain.

In the Nebula marketplace consumers for the first time can receive compensation for their health data via a cryptocurrency token-based payment system created by Nebula Genomics. This directly addresses consumer concerns over the practice of medical and genomic data brokers to sell personal health data to third parties.

“Compared to centralized databases, Nebula’s decentralized and federated architecture will help address privacy concerns and incentivize data sharing. Our goal is to create a data flow that will accelerate medical research and catalyze a transformation of health care,” added Dennis Grishin, CSO & co-founder of Nebula Genomics.

About Nebula Genomics

Nebula Genomics is a human genome sequencing and health big data company on a mission to usher in the era of genomic sequencing by building a large and trusted genomic and health data marketplace for consumers, researchers and the medical community. Using blockchain to ensure that consumers maintain control of their data and are compensated for its use, the Nebula marketplace will aggregate a critical mass of rich genetic information that researchers can analyze in order to accelerate drug development, streamline clinical trials, and usher in the era of truly personalized medicine. The company was founded by Harvard genomics pioneer George Church, along with Harvard researchers Dennis Grishin and Kamal Obbad. Founded in 2017, Nebula Genomics has offices in San Francisco, CA and Boston, MA and is backed by investors including Khosla Ventures, Arch Venture Partners, Fenbushi Capital, Mayfield, F-Prime Capital Partners, Great Point Ventures, Windham Venture Partners, Hemi Ventures, Mirae Asset, Hikma Ventures and Heartbeat Labs. For more information, follow @NebulaGenomics on Twitter and Facebook or visit nebula.org.

About Veritas Genetics

Veritas is The Genome Company. We screen the majority of an individual’s DNA through whole genome sequencing and interpretation to provide insights on inherited disease risks, carrier status, drug sensitivities, traits and ancestry. Our mission is to help people understand their genetics and make more informed health and lifestyle decisions with the involvement of their physician and access to skilled genetic counselors. Co-founded in 2014 by George Church and leading scientists from the Personal Genome Project at Harvard Medical School, Veritas operates globally from its offices in the U.S., Europe and China. The company has been recognized twice by MIT Technology Review as one of the 50 Smartest Companies in 2016 and 2017, by Fast Company as one of the Most Innovative Companies in the World in 2018, and by CNBC as a 2018 Disruptor 50 Company. For more information, follow @VeritasGenetics on Facebook and Twitter or visit veritasgenetics.com. For more information on Arvados, visit arvados.org

Contact information

Nebula Genomics
Louise Callagy
CMO
louise@nebula.org
press@nebula.org
or
Veritas
Rodrigo Martinez
Chief Marketing & Design Officer
rodrigo@veritasgenetics.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

PV InfoLink to Host Dialogues with Industry Heavyweights on 2H19 Solar Market Outlook Prior To SNEC23.4.2019 07:00:00 CESTPressemelding

A seminar titled “2H19 PV Market Outlook and Forecast” will be held in Shanghai on June 3, one day prior to SNEC, to discuss global supply chain market outlook in the second half of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190423005391/en/ 2019 Module Prices and Demand Forecast. (Photo: Business Wire) Held by PV InfoLink, a leading solar market intelligence provider, the seminar will bring together PV manufacturers, developers, EPC, and investors to explore major issues revolving the industry and help participants gain valuable insights for navigating the expanding solar market. PV InfoLink has invited Chinese major companies, including Jinko, Longi, and GCL-Si, to discuss impact of China’s transition to a subsidy-free market. This year, China’s demand will revive later than usual due to policy uncertainty. Moreover, Japan and India, China’s two major trading partners, saw weakening demand after the end of f

JPND Launches Updated Research and Innovation Strategy23.4.2019 06:45:00 CESTPressemelding

The EU Joint Programme – Neurodegenerative Disease Research (JPND) initiative 1 has launched its updated global Research and Innovation Strategy (RIS) , to provide a unified framework for the support of world class research into neurodegenerative diseases. Neurodegenerative diseases are one of the world’s leading medical and societal challenges and there are now expected to be 50 million people worldwide suffering from Alzheimer’s disease and related disorders. Globally, these numbers show no signs of abating, and it is estimated that by 2050 in Europe alone, the total direct and informal care costs for Alzheimer’s and Parkinson’s disease will exceed €350 billion annually.2 JPND is the first and largest collaborative research initiative established to tackle the growing challenge posed by neurodegenerative diseases. JPND’s ultimate goal is to accelerate the discovery of a cure and to enable early diagnosis for early personalised treatments. In the meantime, it is essential to implement

Comprehensive Tumor Profiling Promises New Therapeutic Options for Patients with Advanced Cancer22.4.2019 15:00:00 CESTPressemelding

Published in Nature Medicine* today, results of WINTHER, the first study pioneered by the WIN Consortium** - - Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial - shows that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling for tumor mutations alone. The WINTHER trial***, NCT01856296, led by investigators from Vall d’Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave Roussy (France) (Jean-Charles Soria), Centre Léon Bérard (France) (Pierre Saintigny), Segal Cancer Centre, McGill University (Canada) (Wilson H. Miller), UT MD Anderson Cancer Center (USA) (Jordi Rodon and Apostolia-Maria Tsimberidou) and University of California San Diego, Moores Cancer Center (USA) (Razelle Kurzrock), aimed to expand precision oncology to patients with advanced solid tumors that progressed after treatment with standard therapies. For

PPG Advances Sustainability to Protect and Beautify the World22.4.2019 14:13:00 CESTPressemelding

PPG (NYSE:PPG) today published its 2018 Sustainability Report, detailing the company’s performance and progress against its 2025 sustainability goals that contribute to its purpose and promise: WE PROTECT AND BEAUTIFY THE WORLD™. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190422005156/en/ PPG highlights progress against key economic, environment and social goals in its 2018 Sustainability Report. (Graphic: Business Wire) Last year, PPG embedded additional sustainable practices into its operations, introduced new sustainably advantaged products for customers, achieved a record low in injury cases across the company, advanced its global community engagement initiatives, and further advanced its diversity and inclusion efforts. The report is available at sustainability.ppg.com. “Our dedicated workforce continues to drive sustainability deeper into our global operations,” said Michael H. McGarry, PPG chairman and chief execu

Standard Bank Moves Business to the Cloud with Moody’s Analytics22.4.2019 13:00:00 CESTPressemelding

Moody’s Analytics, a global provider of financial intelligence, announced today that Johannesburg-based Standard Bank Group has selected the Moody’s Analytics CreditLens™ solution to digitize and automate its credit processes. Built on the latest cloud-based technology, the CreditLens platform helps financial institutions digitally transform their commercial credit processes to make faster and better-informed credit decisions. With $148 billion in assets, Standard Bank Group is the largest bank in Africa by that measure. It offers banking and financial services across 20 countries in sub-Saharan Africa. This extensive footprint is part of what led the bank to pursue a cloud-based platform. “It was becoming less and less efficient to have our systems on premise across so many segments and regions, so the idea that the CreditLens platform will always be up to date with product enhancements pushed through the cloud is extremely appealing to us,” said Gordon Turnbull, Head of Credit for Bu

Landmark Deal Puts Coca-Cola at the Heart of the Entertainment Industry in MENA as the UAE’s First Indoor Venue is Named the Coca-Cola Arena22.4.2019 10:04:00 CESTPressemelding

The Coca-Cola Company (TCCC) has signed a 10-year agreement for the exclusive naming rights of the brand new indoor multipurpose arena in Dubai. Now known as the Coca-Cola Arena, the breath-taking venue is the largest of its kind between Istanbul to Singapore and will further establish Dubai as a major destination for world music tours, sporting competitions, family shows and corporate events. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190422005299/en/ The Coca-Cola Arena, Dubai (Photo: AETOSWire) The venue, with an impressive capacity of 17,000, is scheduled to open in June this year. The Coca-Cola Arena will put Coca-Cola at the centre of the entertainment landscape in the region and will join a growing number of entertainment venues around the world where Coca-Cola is served. Up there with iconic locations like Piccadilly Circus in London or Times Square in New York City; the latest addition to the Dubai skyline will